These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 9475275

  • 1. Acute renal effects of AT1-receptor blockade after exogenous angiotensin II infusion in healthy subjects.
    Schmitt F, Martinez F, Brillet G, Nguyen-Khoa T, Brouard R, Sissmann J, Lacour B, Grunfeld JP.
    J Cardiovasc Pharmacol; 1998 Feb; 31(2):314-21. PubMed ID: 9475275
    [Abstract] [Full Text] [Related]

  • 2. Renal effects of angiotensin I-receptor blockade and angiotensin convertase inhibition in man.
    Schmitt F, Natov S, Martinez F, Lacour B, Hannedouche TP.
    Clin Sci (Lond); 1996 Mar; 90(3):205-13. PubMed ID: 8777826
    [Abstract] [Full Text] [Related]

  • 3. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects.
    Burnier M, Hagman M, Nussberger J, Biollaz J, Armagnac C, Brouard R, Weber B, Brunner HR.
    Hypertension; 1995 Apr; 25(4 Pt 1):602-9. PubMed ID: 7721404
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of the acute effects of angiotensin II by the receptor antagonist irbesartan in normotensive men.
    Ribstein J, Picard A, Armagnac C, Sissmann J, Mimran A.
    J Cardiovasc Pharmacol; 2001 Apr; 37(4):449-60. PubMed ID: 11300658
    [Abstract] [Full Text] [Related]

  • 5. Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men.
    McIntyre M, MacFadyen RJ, Meredith PA, Brouard R, Reid JL.
    J Cardiovasc Pharmacol; 1996 Jul; 28(1):101-6. PubMed ID: 8797143
    [Abstract] [Full Text] [Related]

  • 6. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects.
    Burnier M, Rutschmann B, Nussberger J, Versaggi J, Shahinfar S, Waeber B, Brunner HR.
    Hypertension; 1993 Sep; 22(3):339-47. PubMed ID: 8349327
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Opposing effects of angiotensin II on muscle and renal blood flow under euglycemic conditions.
    Fliser D, Dikow R, Demukaj S, Ritz E.
    J Am Soc Nephrol; 2000 Nov; 11(11):2001-2006. PubMed ID: 11053475
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Failure of angiotensin II to suppress plasma renin activity in normotensive subjects with a positive family history of hypertension.
    Herlitz H, Palmgren E, Widgren B, Aurell M.
    Clin Sci (Lond); 2005 Sep; 109(3):311-7. PubMed ID: 15901242
    [Abstract] [Full Text] [Related]

  • 11. Pharmacodynamic studies on the angiotensin II type 1 antagonists irbesartan and candesartan based on angiotensin II dose response in humans.
    Belz GG, Butzer R, Kober S, Mutschler E.
    J Cardiovasc Pharmacol; 2002 Apr; 39(4):561-8. PubMed ID: 11904530
    [Abstract] [Full Text] [Related]

  • 12. Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension.
    van den Meiracker AH, Admiraal PJ, Janssen JA, Kroodsma JM, de Ronde WA, Boomsma F, Sissmann J, Blankestijn PJ, Mulder PG, Man In 't Veld AJ.
    Hypertension; 1995 Jan; 25(1):22-9. PubMed ID: 7843749
    [Abstract] [Full Text] [Related]

  • 13. Influence of AT1 receptor blockade on blood pressure, renal haemodynamics and hormonal responses to intravenous angiotensin II infusion in hypertensive patients.
    Fridman KU, Elmfeldt D, Wysocki M, Friberg PR, Andersson OK.
    Blood Press; 2002 Jan; 11(4):244-52. PubMed ID: 12361194
    [Abstract] [Full Text] [Related]

  • 14. Prevention of hypertension by irbesartan in Dahl S rats relates to central angiotensin II type 1 receptor blockade.
    Leenen FH, Yuan B.
    Hypertension; 2001 Mar; 37(3):981-4. PubMed ID: 11244027
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Renal response to angiotensin after short-term angiotensin converting enzyme inhibition.
    Hannedouche T, Schmitt F, Ikeni A, Marques LP, Natov S, Déchaux M, Lacour B, Grünfeld JP.
    Hypertension; 1993 Mar; 21(3):261-6. PubMed ID: 7682991
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Renal actions of the selective angiotensin AT2 receptor ligands CGP 42112B and PD 123319 in the sodium-depleted rat.
    Macari D, Bottari S, Whitebread S, De Gasparo M, Levens N.
    Eur J Pharmacol; 1993 Nov 02; 249(1):85-93. PubMed ID: 8282023
    [Abstract] [Full Text] [Related]

  • 19. Influence of irbesartan and enalapril on changes of renal function associated with the established phase of l-NAME hypertension.
    Jover B, Herizi A, Casellas D, Mimran A.
    J Hypertens; 2001 Nov 02; 19(11):2039-46. PubMed ID: 11677370
    [Abstract] [Full Text] [Related]

  • 20. Renal safety of combined cyclooxygenase 2 (COX-2) inhibitor and angiotensin II receptor blocker administration in mild volume depletion.
    Kistler T, Ambühl PM.
    Swiss Med Wkly; 2001 Apr 07; 131(13-14):193-8. PubMed ID: 11345810
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.